Amarantus Bioscience Holdings Inc (AMBS) Financial Statements (2024 and earlier)

Company Profile

Business Address 655 MONTGOMERY STREET
SAN FRANCISCO, CA 94111
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2016
MRQ
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 176,000214,0001,032,634157,174
Cash and cash equivalents 176,000214,0001,032,634157,174
Prepaid expense and other current assets519,620
Other undisclosed current assets 652,000198,000215,186 
Total current assets: 828,000412,0001,247,820676,794
Noncurrent Assets
Property, plant and equipment 115,000145,000  
Intangible assets, net (including goodwill), including: 2,861,0001,497,000611,094
Goodwill 7,967,000   
Intangible assets, net (excluding goodwill) 2,861,0001,497,000611,094 
Other undisclosed intangible assets, net (including goodwill) (7,967,000) 
Other undisclosed noncurrent assets 7,967,000204,000 533,143
Total noncurrent assets: 10,943,0001,846,000611,094533,143
TOTAL ASSETS: 11,771,0002,258,0001,858,9141,209,937
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 7,723,0003,527,0001,263,5942,596,848
Interest and dividends payable 195,00025,000  
Accounts payable  3,353,000971,1992,596,848
Accrued liabilities  149,000292,395 
Other undisclosed accounts payable and accrued liabilities 7,528,000   
Debt 1,000,000 931,942740,000
Derivative instruments and hedges, liabilities 5,098,000 5,859,17026,893
Due to related parties 257,000252,000247,967222,083
Other undisclosed current liabilities 2,114,0002,550,000236,5171,151,929
Total current liabilities: 16,192,0006,329,0008,539,1904,737,753
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 1,113,000   
Total noncurrent liabilities: 1,113,000   
Total liabilities: 17,305,0006,329,0008,539,1904,737,753
Temporary equity, carrying amount 3,154,000   
Equity
Equity, attributable to parent, including: (8,688,000)(4,071,000)(7,519,170)(3,527,816)
Common stock 21,000842,000574,172342,517
Additional paid in capital 74,767,00045,050,00018,938,0397,991,465
Accumulated deficit (92,241,000)(55,183,000)  
Other undisclosed equity, attributable to parent 8,765,0005,220,000(27,031,381)(11,861,798)
Other undisclosed equity   838,894 
Total equity: (8,688,000)(4,071,000)(6,680,276)(3,527,816)
TOTAL LIABILITIES AND EQUITY: 11,771,0002,258,0001,858,9141,209,937

Income Statement (P&L) (USD)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Operating expenses (24,821,000)(21,354,000)(5,711,134)(4,096,473)
Other operating expense, net
(Other Expenses)
  (9,000)  
Other undisclosed operating income (loss)  9,000 (1,039,145)
Operating loss: (24,821,000)(21,354,000)(5,711,134)(5,135,618)
Nonoperating income (expense) (393,000)(5,923,000)(9,420,547)485,006
Investment income, nonoperating 4,105,000317,000271,191485,006
Interest and debt expense (1,296,000)(2,063,000)(9,339,642) 
Loss from continuing operations before equity method investments, income taxes: (26,510,000)(29,340,000)(24,471,323)(4,650,612)
Other undisclosed income from continuing operations before income taxes 1,297,0002,062,0009,340,642 
Loss from continuing operations: (25,213,000)(27,278,000)(15,130,681)(4,650,612)
Loss before gain (loss) on sale of properties: (25,213,000)(27,278,000)(15,130,681)(4,650,612)
Other undisclosed net income    560,270
Net loss: (25,213,000)(27,278,000)(15,130,681)(4,090,342)
Other undisclosed net income (loss) attributable to parent (1,000)1,000(1,000)(1,045,276)
Net loss attributable to parent: (25,214,000)(27,277,000)(15,131,681)(5,135,618)
Preferred stock dividends and other adjustments (3,595,000)(875,000)(38,402) 
Other undisclosed net loss available to common stockholders, basic (8,249,000)   
Net loss available to common stockholders, basic: (37,058,000)(28,152,000)(15,170,083)(5,135,618)
Convertible preferred dividends (8,249,000)   
Net loss available to common stockholders, diluted: (45,307,000)(28,152,000)(15,170,083)(5,135,618)

Comprehensive Income (USD)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (25,213,000)(27,278,000)(15,130,681)(4,090,342)
Comprehensive loss, net of tax, attributable to parent: (25,213,000)(27,278,000)(15,130,681)(4,090,342)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: